UBS lowered the firm’s price target on Cintas (CTAS) to $228 from $235 and keeps a Buy rating on the shares. Cintas delivered 8.2% organic growth despite minimal payroll growth, with EPS meeting but not exceeding expectations, potentially due to SG&A timing, the analyst tells investors in a research note. Raised full-year guidance and accelerating EBIT margins, combined with a de-rated multiple, suggest an attractive opportunity relative to long-term value from the pending UniFirst deal.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTAS:
- Cintas price target lowered to $190 from $222 at Stifel
- Cintas price target lowered to $213 from $236 at Goldman Sachs
- Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
- Cintas: Robust Organic Growth, Expanding Margins, and Strong Balance Sheet Underpin Buy Rating
- Cintas reports Q3 EPS $1.24, consensus $1.24
